AML Registry to transform blood cancer research with the help of AI

Acute Myeloid Leukaemia (AML) is an aggressive blood cancer that spreads quickly and as a result requires immediate treatment.

Although a rare condition, it is still one of the most common acute blood cancers. But outcomes for the disease have traditionally been poor, despite some success in randomized trials. Therefore, says Professor Charles Craddock, Professor of Haemato-Oncology at Warwick University and Chair of the AML Research Network:

The UK AML community realized a few years ago that by collecting high-quality prospective registry data, we could get really quite profound insights that would teach us how to improve treatment outcomes. So, at the same time as working hard to deliver a platform of prospective randomized trials, we recognized as a group that we needed to identify funding to set up an AML Registry.

Such registries, or databases, store both patient and disease information. Doctors and researchers can then analyze this data ...